2008-07-04 20:31:17 - www.companiesandmarkets.com adds new report - Premium Company Profile - Tanox

www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction

Tanox identifies and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of immunology, infectious diseases and cancer. In January 2007, the stockholders of Tanox approved the merger with Genentech for $20 per share for a total cash value of approximately $919 million



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed

business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

Tanox is a biopharmaceutical company focused on discovering and developing therapeutic monoclonal antibodies that influence or are derived from the immune system.



The company´s therapeutic emphasis is on the areas of immunology (asthma/allergy and autoimmune diseases), infectious diseases, and oncology.



Tanox derives its revenues from royalties, license fees, development and manufacturing right, and profit sharing for its humanized monoclonal antibody product, Xolair.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization